Bristol Myers Squibb (NYSE: BMY) has confirmed the conclusion of its tender offer, initially announced, to acquire all outstanding shares of RayzeBio, Inc. (Nasdaq: RYZB) common stock at a price of $62.50 per share in cash, totaling approximately $4.1 billion. The offer expired at one minute after 11:59 p.m., Eastern Time, on February 22, 2024.
According to Equiniti Trust Company, the depositary for the offer, as of the Expiration Time, about 53,052,499 shares of RayzeBio common stock were validly tendered and not withdrawn, constituting roughly 86% of the issued and outstanding shares of RayzeBio common stock at that time.
The transaction is anticipated to close on February 26, 2024, following the acceptance of all shares of common stock validly tendered and not withdrawn pursuant to the offer.
RayzeBio stockholders with inquiries about the offer can reach out to Georgeson LLC, the information agent for the offer, toll-free at 1-888-815-8542 or via email at rayzebio@georgeson
Bristol Myers Squibb is a global biopharmaceutical company dedicated to discovering, developing, and delivering innovative medicines to help patients overcome serious diseases. For more information, visit BMS.com or follow the company on LinkedIn, Twitter, YouTube, Facebook, and Instagram.
Additional Information about the Tender Offer and Where to Find It:
This communication serves for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell any shares of RayzeBio common stock or any other securities. Investors and security holders are advised to carefully review both the tender offer materials and the solicitation/recommendation statement regarding the offer, as they may contain vital information. These documents are available on the SEC’s website at www.sec.gov or by contacting the information agent for the offer. They can also be accessed for free on Bristol Myers Squibb’s website at www.bms.com/investors.
Cautionary Statement Regarding Forward-Looking Statements:
This communication contains forward-looking statements concerning the acquisition of RayzeBio by Bristol Myers Squibb. These statements are based on current expectations and involve inherent risks and uncertainties. Actual results may differ materially from current expectations due to various factors, including risks associated with the timing of the merger closing, potential benefits realization, legal proceedings, and unforeseen challenges related to the transaction. Forward-looking statements should be evaluated in conjunction with the uncertainties affecting Bristol Myers Squibb’s business, as detailed in its filings with the U.S. Securities and Exchange Commission. Bristol Myers Squibb undertakes no obligation to publicly update any forward-looking statement, except as required by law.
